QIAGEN Announces Supply Agreement with Beckman Coulter , Inc. to Provide Sample Preparation Kits for the Vidiera™ NsP Platform
May 09 2005

QIAGEN Announces Supply Agreement with Beckman Coulter , Inc. to Provide Sample Preparation Kits for the Vidiera™ NsP Platform

Venlo, the Netherlands - May 9, 2005: QIAGEN N.V. (NASDAQ: QGEN, Frankfurt, Prime Standard: QIA) today announced that its wholly owned subsidiary QIAGEN GmbH has entered into a manufacturing and supply agreement with Beckman Coulter, Inc. (NYSE: BEC). Beckman Coulter intends to market two of QIAGEN's automated sample preparation kits for use with their new Vidiera NsP nucleic acid sample preparation platform.

 

The two customized kits will incorporate a modified version of QIAGEN's market and technology leading QIAamp® technology for automated and reliable purification of viral nucleic acids from serum and plasma samples, as well as genomic DNA from blood samples. QIAGEN's proprietary nucleic acid sample preparation kits provide highest reliability and efficiency in both DNA and RNA separation and purification for molecular diagnostics applications.

 

"We are very pleased to be supporting Beckman Coulter with QIAGEN's nucleic acid purification solutions for their automated Vidiera NsP platform," said Dr. Frank Krieg-Schneider, QIAGEN's Executive Director Strategic Alliances. "The strategic alliance with Beckman Coulter emphasizes QIAGEN's leading position as the provider of standardized technologies for molecular diagnostics. Reproducible extraction and purification of nucleic acids are important for success in providing sensitive and reliable nucleic acid testing."

"QIAGEN's world class filtration sample purification and isolation kits are key to Beckman Coulter's strategy of providing leading automated solutions for molecular diagnostics laboratories," said Bernhard Spiess, director of Beckman Coulter's Nucleic Acid Business Center. "With QIAGEN's technology and our new Vidiera NsP platform, we are now able to provide innovative automated solutions for sample preparation that will simplify molecular diagnostic laboratory processes."

 

 

About QIAGEN:

 

QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, Sweden, and the Netherlands believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins. QIAGEN has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid and protein separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, QIAGEN is positioning its products for sale into developing commercial markets, including applied testing markets, clinical research, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs more than 1,300 people worldwide. Further information on QIAGEN can be found at http://www.qiagen.com/.

 

 

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the applied testing markets and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products ( including fluctuations for certain events including funding, budgets, and others ), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, market acceptance of QIAGEN's new products and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

 

###

 

 

Contact:

IR QIAGEN N.V.

Phone: +49 2103 29 11710

Fax: +49 2103 29 21710

Email: ir@qiagen.com

SOCIAL SHARING

Share this page